New treatment for orbital non-Hodgkin's lymphoma: 2 Cases treated with rituximab;Nouvelle approche thérapeutique du lymphome malin non Hodgkinien orbitaire: À propos de deux cas traités par rituximab

Journal Francais d'Ophtalmologie

Volumn 28, Issue 7, 2005, Pages 769-771

  Benabid, L ^a   Desablens, B ^a   Defossez, T ^a   Malthieu, D ^a   Milazzo, S ^a   Turut, P ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Immunohistochemistry; Immunology; Immunotherapy; Orbital non Hodgkin's lymphoma

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; CONJUNCTIVA TUMOR; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EYELID TUMOR; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; ORBIT TUMOR; SIDE EFFECT; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR REGRESSION;

EID: 26944494501     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(05)80991-x     Document Type: Article

References (12)

1. Aisenberg AC. Malignant lymphoma: biology, natural history, and treatment. Philadelphia, MA, Lea and Febiger, 1991.
2. Bolek TW, Moyses HM, Marcus RB Jr, Gorden L 3rd, Maiese RL, Almasri NM et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys, 1999;44:31-6.
3. Lachapelle K, Rathee R, Kratky V, Dexter DF. Treatment of conjunctival mucosa associated lymphoid tissue lymphoma with intralesional injection of interferon alfa 2b. Arch Ophthalmol, 2000;118:284-5.
4. Blasi MA, Gherinzoni F, Calvisi G, Sasso P, Tani M, Cellini M et al. Local chemotherapy with interferon alpha for conjunctival mucosa associated lymphoid tissue lymphoma. Ophthalmology, 2001;108:559-62.
5. Eicher MD, Fraunfelder FT. Cryotherapy for conjunctival lympoid tumors. Am J Ophthalmol, 1994;118:463-7.
6. Hainsworth JD, Litchy S, Burris HA 3rd. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol, 2002;20:4261-7.
7. Reyes F. Les lymphomes malins non-Hodgkiniens. Collection FMC Hématologie 2000, John Libbey Eurotext, Paris.
8. Conconi A, Martinelli G, Thieblemont C. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of Malt type. Blood, 2003;102:2741-5.
9. Colombat P, Salles G, Brousse N. Rituximab (anti-CD 20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 2001;97:101-6.
10. Schultze JL, Nadler LM. T-cell mediated immunotherapy for B-cell lymphoma. J Mol Med, 1999;77:3222-31.
11. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-hodgkin's lymphomas. N Engl J Med, 1984;311:1471-5.
12. Mounier N, Gisselbrecht C. Anticorps monoclonaux dans le traitement des lymphomes. Rev Prat, 2002;52:982-5.